Guidelines for chemotherapy for Spinal TB in india
spinal tuberculosis chemotherapy treatment regimen India guidelines
Pott's disease antitubercular therapy duration drugs RNTCP
tuberculosis treatment regimen 2HRZE 4HR India NTEP national program
extrapulmonary tuberculosis osteoarticular treatment duration rifampicin isoniazid pyrazinamide ethambutol
| Duration | Drugs | Abbreviation |
|---|---|---|
| 2 months | Isoniazid (H) + Rifampicin (R) + Pyrazinamide (Z) + Ethambutol (E) | 2HRZE |
| Duration | Drugs | Abbreviation |
|---|---|---|
| 4–7 months | Isoniazid (H) + Rifampicin (R) | 4–7HR |
Total Duration: 6–9 months for drug-susceptible spinal TB.
| Clinical Scenario | Recommended Duration |
|---|---|
| Uncomplicated spinal TB (no neurological deficit, no extensive bony destruction) | 6 months (2HRZE + 4HR) |
| Complicated disease / neurological involvement / slow responder | 9 months (2HRZE + 7HR) |
| Spinal TB with meningeal involvement | 9–12 months (managed as TBM) |
| Extensive orthopedic hardware in situ | Up to 12 months |
| MDR-TB | Longer individualized regimens per DST |
| Drug | Daily Dose |
|---|---|
| Isoniazid (H) | 5 mg/kg (max 300 mg/day) |
| Rifampicin (R) | 10 mg/kg (max 600 mg/day) |
| Pyrazinamide (Z) | 25–30 mg/kg (max 2 g/day) |
| Ethambutol (E) | 15–20 mg/kg (max 1.6 g/day) |
Chemotherapy alone is adequate for uncomplicated spinal TB. Multiple trials have shown no additional benefit of surgical debridement over chemotherapy alone (Treatment of Drug-Susceptible Tuberculosis, p. 31).
| Resistance Pattern | Regimen |
|---|---|
| MDR-TB (resistant to H + R) | Individualized regimen per DST; typically 18–20 months using Group A drugs (Bedaquiline, Levofloxacin, Linezolid) |
| XDR-TB | Further individualized; longer duration |
| INH-mono-resistance | 6 months of RZES or 9 months of RZE |
| Parameter | Recommendation |
|---|---|
| First-line regimen | 2HRZE + 4HR (total 6 months) |
| Complicated/slow response | 2HRZE + 7HR (total 9 months) |
| Drug delivery | Daily FDCs under DOTS |
| Program | NTEP (free drugs via government) |
| Surgery | Only for specific indications |
| MDR-TB | DST-guided individualized regimen |
what are the guidelines for chemotherapy in other osteoarticular TB
osteoarticular tuberculosis chemotherapy treatment guidelines peripheral joint bone
tuberculous arthritis hip knee treatment regimen duration antitubercular
| Phase | Regimen | Duration |
|---|---|---|
| Intensive phase | Isoniazid (H) + Rifampicin (R) + Pyrazinamide (Z) + Ethambutol (E) | 2 months |
| Continuation phase | Isoniazid (H) + Rifampicin (R) | 4–7 months |
| Total | 6–9 months |
According to Treatment of Drug-Susceptible Tuberculosis (p. 31): "Six- to 9-month regimens containing Rifampicin for treatment of bone, joint, and spinal tuberculosis are at least as effective as 18-month regimens that do not contain Rifampicin."
| Site / Scenario | Recommended Total Duration |
|---|---|
| Peripheral joint TB (hip, knee, etc.) — uncomplicated | 6 months |
| Peripheral joint TB with extensive destruction or slow response | 9 months |
| TB dactylitis (children) | 6 months |
| TB osteomyelitis of long/flat bones | 6–9 months |
| Osteoarticular TB in children (AAP/expert opinion) | Extend continuation phase → up to 9–12 months total |
| Extensive hardware/prosthesis in situ | Up to 12 months |
| MDR osteoarticular TB | DST-guided; typically 18–20 months |
| Indication | Procedure |
|---|---|
| Non-resolving abscess | Aspiration or open drainage |
| Destroyed joint with severe dysfunction | Arthrodesis or arthroplasty (after disease quiescence) |
| Failure of medical therapy / diagnostic uncertainty | Biopsy + debridement |
| TB tenosynovitis with nerve compression (e.g., carpal tunnel) | Decompression + synovectomy |
| Parameter | Timing |
|---|---|
| Clinical assessment (pain, swelling, function) | Monthly |
| X-ray of affected joint | Baseline, 3 months, end of treatment |
| MRI | Baseline for complex cases; repeat if poor response |
| LFTs | Baseline, 2 weeks, 4 weeks, then as indicated |
| Visual acuity/color vision (Ethambutol) | Baseline, then monthly |
| ESR / CRP | Baseline and periodically (supports response assessment) |
| Feature | Guideline |
|---|---|
| Regimen | 2HRZE + 4HR (standard) |
| Total duration | 6 months (uncomplicated); 9 months (complex/children) |
| Program (India) | NTEP — daily FDCs, free, under DOTS |
| Surgery | Reserved; not routine |
| Children | Extend continuation phase; prefer 9 months total |
| MDR disease | DST-guided individualized regimen |
degas osteotomy
Degas osteotomy technique indications hip tuberculosis
Degas osteotomy hip surgery diagram
Degas osteotomy displacement hip intertrochanteric femoral head avascular necrosis
intertrochanteric osteotomy hip TB destroyed joint ankylosis surgical treatment
The goal is a pain-free, stable, mobile pseudarthrosis or fibrous ankylosis at a functional position.
| Indication | Detail |
|---|---|
| Hip TB with destroyed joint | Stage IV TB hip (advanced destruction of femoral head and acetabulum) |
| Young patients (<40–45 years) in whom THA is not yet appropriate | Avoids prosthesis in a young, active individual |
| Failed conservative ATT with persistent pain and disability | After adequate chemotherapy (typically ≥6 months ATT) |
| Pathological dislocation of the hip secondary to TB | To restore limb length and stability |
| Fibrous or bony ankylosis in a bad position | To reposition the limb in a better functional alignment |
| Outcome Measure | Expected Result |
|---|---|
| Pain relief | Good to excellent in 70–85% of cases |
| Mobility | Functional range of motion (especially abduction/flexion for sitting cross-legged — important for Indian patients) |
| Stability | Satisfactory weight-bearing in most patients |
| Limb shortening | 2–3 cm (correctable with shoe raise) |
| Conversion to THA | Can be performed later once TB is fully quiescent (≥2 years) |
| Procedure | Age Group | Advantages | Disadvantages |
|---|---|---|---|
| Degas osteotomy | Young (<45 yrs) | Biologic, no implant in infected field, preserves bone for future THA | Limb shortening, Trendelenburg gait |
| Girldlestone's excision arthroplasty | Any | Simple, removes infected tissue | Flail hip, significant shortening, poor function |
| Arthrodesis (fusion) | Young active | Stable, pain-free | Loss of mobility, stress on adjacent joints |
| Total hip arthroplasty | Older (>50 yrs) / quiescent TB | Best functional outcome | Risk of reactivation, high revision rate in young patients |
degas osteotomy of peivis
Degas osteotomy pelvis pelvic tuberculosis surgical technique
Degas osteotomy pelvis diagram illustration
innominate osteotomy acetabular dysplasia Salter Chiari pelvic osteotomy types
pelvic osteotomy acetabular redirection coverage femoral head hip dysplasia
Iliac crest
|
| ← Osteotomy line runs here (oblique/curved)
| through the body of the ilium
Acetabulum (diseased/destroyed in TB)
|
Femoral head
| Component | Location | Purpose |
|---|---|---|
| Pelvic (iliac) osteotomy | Through ilium above acetabulum | Frees acetabular segment; allows repositioning |
| Femoral (subtrochanteric) osteotomy | Below lesser trochanter | Displaces femoral shaft medially |
| Net result | Hip joint complex repositioned | Destroyed joint displaced; new weight-bearing surface created |
| Indication | Rationale |
|---|---|
| Severe acetabular destruction by TB | The pelvic cut allows the acetabular rim to be repositioned |
| Pathological dislocation of the hip | Relocating the femoral head requires freeing both sides of the joint |
| Lateral uncoverage of femoral head | Pelvic cut redirects acetabulum to improve coverage |
| Combined femoral head + acetabular TB destruction | Both cuts needed for full repositioning |
| Procedure | Age Group | Mechanism | TB Application |
|---|---|---|---|
| Degas (pelvic component) | Any (mainly young adults/children) | Displacement + redirection of acetabular fragment | TB-destroyed hip with acetabular involvement |
| Salter innominate osteotomy | Children <8 yrs | Rotates entire acetabulum anterolaterally | Hip dysplasia; occasionally post-TB dysplasia |
| Chiari osteotomy | Older children/adults | Medial displacement of ilium; creates bony shelf | Salvage for dysplasia; also used in TB sequelae |
| Triple osteotomy (Steel/Tönnis) | Adolescents/young adults | Three cuts around acetabulum for full redirection | Hip dysplasia |
| Periacetabular osteotomy (PAO/Ganz) | Adults | Maximum acetabular redirection with preserved blood supply | Hip dysplasia |
radiating pain vs reffred pain
radiating pain versus referred pain difference mechanism pathophysiology
referred pain convergence theory dermatome visceral somatic examples
| Feature | Radiating Pain | Referred Pain |
|---|---|---|
| Definition | Pain that travels/spreads along the course of a nerve from its origin | Pain perceived at a site distant from the actual source, without traveling along an obvious nerve path |
| Mechanism | Direct nerve irritation or compression — pain follows the anatomical distribution of that nerve | Convergence-projection — afferent fibers from two different sites converge on the same second-order spinal neuron; the brain misidentifies the source |
| Path | Follows a predictable dermatomal or nerve distribution | Does not follow a nerve distribution; location is anatomically unrelated to the source |
| Quality | Often sharp, shooting, electric, lancinating | Often dull, aching, poorly localized |
| Neurological signs | May be accompanied by paresthesia, numbness, weakness in the nerve distribution | Usually no neurological deficits |
| Source | Nervous tissue itself is irritated (nerve root, peripheral nerve) | Visceral or deep somatic structure is the source |
| Source | Nerve/Root | Distribution of Radiation |
|---|---|---|
| L4–L5 disc herniation | L5 root | Back → buttock → lateral leg → dorsum of foot |
| L5–S1 disc herniation | S1 root | Back → buttock → posterior thigh → sole of foot |
| Carpal tunnel syndrome | Median nerve | Wrist → thumb, index, middle fingers |
| Cervical spondylosis (C6) | C6 root | Neck → shoulder → lateral forearm → thumb |
| Brachial neuritis | Brachial plexus | Shoulder → arm → hand |
| Actual Source | Site of Perceived Pain | Shared Spinal Level |
|---|---|---|
| Myocardial ischemia | Left arm, jaw, epigastrium | T1–T4 |
| Diaphragm irritation (blood/pus) | Tip of shoulder (C4 dermatome) | C3–C5 |
| Ureteric stone | Groin, ipsilateral testis/labia | T10–L1 |
| Appendicitis (early) | Periumbilical region | T10 |
| Hip joint pathology | Knee pain | L3 (obturator nerve) |
| Cholecystitis | Right shoulder tip, right scapula | C3–C5, T5–T9 |
| Peptic ulcer | Epigastrium radiating to back | T6–T10 |
| Pancreatitis | Band-like pain to back | T6–T10 |
| Clinical Clue | Radiating Pain | Referred Pain |
|---|---|---|
| Distribution | Dermatomal / nerve territory | Non-dermatomal, segmental but diffuse |
| Neurological exam | Positive — sensory loss, weakness, reflex change | Negative — no neurological deficit |
| Straight leg raise / nerve tension tests | Often positive | Negative |
| Palpation at referred site | Not tender (pain not reproduced locally) | Mild tenderness possible (secondary hyperalgesia) |
| Paresthesia | Common (pins and needles, numbness) | Absent |
| Character | Sharp, electric, shooting | Dull, deep, aching |
| Aggravated by movement | Yes (nerve stretch) | Not consistently |
Radiating pain = the nerve itself is the problem; pain travels along the nerve path with neurological signs.
Referred pain = the brain is misled by convergent neural inputs; pain appears at a distant site with no neurological deficit and no direct neural pathway connecting the two sites.